Stayble Therapeutics publishes interim report for the third quarter of 2024
Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its interim report for the third quarter of 2024. The report is available as an attached document and on the Company’s website: https://staybletherapeutics.com/investor-relations/financial-reports/. Below is a summary of the report.Summary Highlights during the second quarter (July – Septmeber 2024) · July: Erik Kullgren was announced as the new CFO, effective August 1, 2024. · September: The South African Patent Office became the first authority to approve the Company's patent for the treatment of pain